Scandion Oncology announces that it has been selected for the final round of MATWIN presentations
Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has been selected to present the company for the MATWIN Board and investors.The MATWIN program is an activity installed by the French Government as a collaboration with Pharma companies, investors and patient advocacy groups to accelerate development of future oncology treatments. Projects selected in the MATWIN process are characterized by high quality science and a ground-breaking potential to make a difference for cancer patients. In the selection process candidate projects are on the one hand scrutinized and